top
Search terms
Results 1 - 1 of 1 - ordered by :
Ehjournal

Furthermore, the EMPA-REG OUTCOME trial using the novel antihyperglycaemic agent, empagliflozin,8 a selective sodiumglucose co- transporter inhibitor, significantly reduced cardiovascular mortality; ...

European Heart Journal, ISSUE @ A GLANCE, Thomas F. Lüscher

Date : 07/02/2016